Results 201 to 210 of about 127,252 (263)

Crystal structure of cytochrome P450 NysL and the structural basis for stereo- and regio-selective oxidation of antifungal macrolides. [PDF]

J Biol Chem
Murarka VC, Kim JS, Lamb DC, Kelly SL, Poulos TL, Follmer AH.   +5 more
europepmc   +1 more source

Mechanistic Insights and Pharmacological Approaches for Nitrogen and Sulfur Mustards and Their Implications as Therapeutic Agents

Journal of Applied Toxicology, EarlyView.
ABSTRACT Nitrogen and sulfur mustards, often acting as vesicants, have significant consequences for public health. Skin is a common site for exposure to these vesicants that can result in considerable morbidity and mortality. Given that the treatment options are limited, new insights into the mechanisms for the toxicity of these vesicants that can be ...
Madison Owens, Anita Thyagarajan, Jeffrey B. Travers, Ravi P. Sahu   +3 more
wiley   +1 more source

Updates on Mechanisms of Cytochrome P450 Catalysis of Complex Steroid Oxidations. [PDF]

Int J Mol Sci
Guengerich FP, Tateishi Y, McCarty KD, Yoshimoto FK.   +3 more
europepmc   +1 more source

Characterization and Expression of the Cytochrome P450 Genes in Daphnia magna Exposed to Cerium Oxide Nanoparticles. [PDF]

Int J Mol Sci
Kang X, Zhou Y, Liu Q, Liu M, Chen J, Zhang Y, Wei J, Wang Y.   +7 more
europepmc   +1 more source

Characterization of a cytochrome P450 that catalyzes the O-demethylation of lignin-derived benzoates. [PDF]

J Biol Chem
Wolf ME, Hinchen DJ, McGeehan JE, Eltis LD.   +3 more
europepmc   +1 more source

Investigation of in silico studies for cytochrome P450 isoforms specificity. [PDF]

Comput Struct Biotechnol J
Wei Y, Palazzolo L, Ben Mariem O, Bianchi D, Laurenzi T, Guerrini U, Eberini I.   +6 more
europepmc   +1 more source

Pharmacokinetics of Atorvastatin and Metformin after Coadministration with Islatravir in Healthy Adults

The Journal of Clinical Pharmacology, EarlyView.
Abstract Islatravir, a deoxyadenosine analog that inhibits HIV‐1 replication by multiple mechanisms of action, including reverse transcriptase translocation inhibition, is being developed for use in HIV‐1 treatment. People living with HIV often have comorbidities, such as dyslipidemia or type 2 diabetes mellitus, necessitating long‐term concomitant ...
Jacqueline B. McCrea, Munjal Patel, Yang Liu, Ryan Vargo, Rose Witter, Andrew Litovsky, S. Aubrey Stoch, Marian Iwamoto, Randolph P. Matthews   +8 more
wiley   +1 more source

Correction: Adaptive evolution of invasive fall armyworms to maize with potential involvement of cytochrome P450 genes. [PDF]

BMC Genomics
Yainna S, Hilliou F, Haenniger S, d'Alençon E, Brévault T, Nam K.   +5 more
europepmc   +1 more source

Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies

The Journal of Clinical Pharmacology, EarlyView.
Abstract Mavacamten is a potential inducer of cytochrome P450 (CYP) 3A4 and could reduce the effectiveness of concomitant drugs that are metabolized by CYP3A4, such as midazolam. This study aimed to determine if repeat doses of mavacamten achieving clinically relevant exposures affected midazolam exposure.
Samira Merali, Caroline Sychterz, Vidya Perera, Lu Gaohua, Victoria Florea, Bindu Murthy   +5 more
wiley   +1 more source

Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review. [PDF]

Cells
Mokhosoev IM, Astakhov DV, Terentiev AA, Moldogazieva NT.   +3 more
europepmc   +1 more source